---
title: "AC Immune Reports Positive Phase 1 Data For PET Tracer ACI-19626 In Diagnosing ALS"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287626218.md"
description: "AC Immune SA (ACIU) reported positive preliminary Phase 1 trial data for its TDP43-PET tracer ACI-19626, showing higher uptake in ALS patients. The findings were presented at the 2026 Summit Advancing TDP43 Biomarkers. The tracer aids in visualizing TDP-43 markers in the brain, crucial for diagnosing neurodegenerative disorders. The trial includes healthy participants and patients with FTD, ALS, and LATE. ACIU's stock closed at $2.83, down 0.70%."
datetime: "2026-05-26T11:20:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287626218.md)
  - [en](https://longbridge.com/en/news/287626218.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287626218.md)
generator: "portal-rs"
---

# AC Immune Reports Positive Phase 1 Data For PET Tracer ACI-19626 In Diagnosing ALS

(RTTNews) - AC Immune SA (ACIU), a clinical-stage biopharmaceutical company, on Friday released new preliminary data from the Phase 1 trial for the TDP43-PET tracer ACI-19626, indicating higher uptake in patients of amyloid lateral sclerosis (ALS). The data was presented at the 2026 Summit Advancing TDP43 Biomarkers hosted by the University of Wisconsin.

TDP-43 is the main component in inclusions found in the brains of patients suffering from certain neurodegenerative disorders like frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), limbic-predominant age-related TDP-43 encephalopathy (LATE), and co-pathologies of Alzheimer's and Parkinson's disease. The diagnosis of these diseases is complex due to the absence of reliable biomarkers. TDP-43 is being explored as a biomarker to specifically diagnose neurological proteinopathies.

The ACI-19626 tracer enables visualization of the TDP-43 markers in the brain using Positron Emission Tomography (PET) scanning.

The ongoing Phase 1 trial for ACI-19626 consists of Part 1, conducted on healthy patients, and Part 2, enrolling up to 30 patients with FTD, ALS, and LATE. Preliminary results suggest a higher uptake of the tracer in patients with ALS, validated with released PET data. 

The study has also established a pharmacokinetic profile of ACI-19626, confirming its suitability in human brain imaging.

ACIU closed Friday at $2.83, down 0.70%. 

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [ACIU.US](https://longbridge.com/en/quote/ACIU.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline](https://longbridge.com/en/news/296519465.md)
- [AC Immune reports positive interim Phase 1 data for NLRP3 inhibitor ACI-19764](https://longbridge.com/en/news/296478492.md)
- [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md)
- [Grey Matters Health signs ProScan to read brain PET scans for Florida NovaScan clinic](https://longbridge.com/en/news/296343901.md)
- [Radiopharm schedules FDA end-of-Phase 2 meeting to align Phase 3 trial design for RAD101 brain metastases imaging agent](https://longbridge.com/en/news/296102289.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**